Mon, Jul 28, 2014, 4:34 AM EDT - U.S. Markets open in 4 hrs 56 mins

Recent

% | $
Click the to save as a favorite.

Seattle Genetics Inc. Message Board

  • mauihope1969 mauihope1969 Mar 10, 2014 12:06 PM Flag

    Why a buy?

    I'm a buyer today. Cantor's sell is right, right, right if your looking at this year's numbers only.
    BUT
    I have no doubt Adcetris will be approved frontline NHL and cd30 B-Cell. That is 10-20 times current approved indications. They now have just about a 2000 patient population which generates $140 ml. Do the math.
    CD-30 cancer is larger than just NHL.
    My peak Adceetris sales estimate is $1.5bil - $2bil. and a $100-$150 2016 share price.
    While looking for stocks which can rise if the market turns down this fits the bill. No debt. No need to raise capital in an offering. Revenue growth which will go exponential.
    SGEN is a no-brainer buy.
    This is just my opinion. I'm long. Do your own research. This is not a recommendation to buy.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SGEN
34.89+0.20(+0.58%)Jul 25 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Puma Biotechnology, Inc.
NYSEFri, Jul 25, 2014 4:01 PM EDT
Sohu.com Inc.
NasdaqGSFri, Jul 25, 2014 3:59 PM EDT